Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma

pubmed: wnt1 2023-05-31


An imbalance between bone resorption and bone formation underlies the devastating osteolytic lesions and subsequent fractures seen in more than 90% of multiple myeloma (MM) patients. Currently, Wnt-targeted therapeutic agents that prevent soluble antagonists of the Wnt signaling pathway, sclerostin (SOST) and dickkopf-1 (DKK1), have been shown to prevent bone loss and improve bone strength in preclinical models of MM. In this study, we show increasing Wnt signaling via a novel anti-low-density...


From feeds:

Exome ยป pubmed: wnt1



Marija K Simic, Sindhu T Mohanty, Ya Xiao, Tegan L Cheng, Victoria E Taylor, Olga Charlat, Peter I Croucher, Michelle M McDonald

Date tagged:

05/31/2023, 20:47

Date published:

03/29/2023, 06:00